Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Kymera Therapeutics Inc., 3 years.
Kymera Therapeutics Inc.
Director
Spyre Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Spyre Therapeutics Inc. | Option exercise | +5,000 | $10.39 | $51,950 |
| Aug 7, 2026 | Spyre Therapeutics Inc. | Open-market sale | −5,000 | $104.47 | $522,350 |
| Aug 7, 2026 | Spyre Therapeutics Inc. | Open-market sale | −8,000 | $104.38 | $835,040 |
| Aug 7, 2026 | Spyre Therapeutics Inc. | Open-market sale | −10,000 | $104.68 | $1,046,800 |
| Dec 8, 2025 | Kymera Therapeutics Inc. | Option exercise | +5,000 | $14.18 | $70,900 |
| Dec 8, 2025 | Kymera Therapeutics Inc. | Open-market sale | −2,748 | $89.32 | $245,451 |
| Dec 8, 2025 | Kymera Therapeutics Inc. | Open-market sale | −2,252 | $90.30 | $203,356 |
| Oct 13, 2025 | Kymera Therapeutics Inc. | Option exercise | +5,000 | $10.34 | $51,700 |
| Oct 13, 2025 | Kymera Therapeutics Inc. | Open-market sale | −5,000 | $59.19 | $295,950 |
| Jun 3, 2025 | Kymera Therapeutics Inc. | Option exercise | +6,349 | $10.34 | $65,649 |
| Jun 3, 2025 | Kymera Therapeutics Inc. | Open-market sale | −6,349 | $49.00 | $311,101 |
| Nov 6, 2024 | Spyre Therapeutics Inc. | Open-market sale | −6,700 | $36.76 | $246,292 |
| Oct 25, 2024 | Spyre Therapeutics Inc. | Open-market sale | −300 | $36.43 | $10,929 |
| Aug 26, 2024 | Kymera Therapeutics Inc. | Option exercise | +5,000 | $10.34 | $51,700 |
| Aug 26, 2024 | Kymera Therapeutics Inc. | Open-market sale | −5,000 | $49.10 | $245,500 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.